Relai, a Switzerland-based Bitcoin-only investment platform, announced the closing of a USD 4.5 million financing. The round was led by ego death capital (EDC), with further participation from Timechain, Cabrit Capital and Lightning Ventures, as well
Bachem Holding successfully placed newly issued shares raising gross proceeds of approximately CHF 584 million by way of an accelerated bookbuilding to finance
As we have informed here, the private equity firm Argos Wityu has acquisted a majority stake in Norline, a leading provider of outsourcing services in the heating, ventilation, air conditioning and plumbing sector in Switzerland.
Credit Suisse and UBS signed a merger agreement, with UBS emerging as the surviving entity. With the combined market capitalization is approximately USD 65 billion, the merger follows negotiations between the two Swiss banks, prompted by
Basel-based orthopedic firm, Medartis, has successfully completed the acquisition of an additional 18% stake in Geneva-based implant manufacturer, KeriMedical, for approximately CHF 18 million. This deal will raise Medartis’ stake to 47%, further cementing the company’s commitment
Kellerhals Carrard advised Verity, creators of the commercially successful inventory tracking solution powered by fully autonomous indoor drones, in the completion of a USD32 million Series B funding round led by A.P. Moller Holding
Seamless Therapeutics, a German biotechnology firm, has successfully concluded a USD12.5 million Seed Financing, a university carve-out including equity financing, in-licensing of an innovative patent portfolio from Technische Universität Dresden and hiring of key
Legal advisors involved in the UBS-Credit Suisse merger: For UBS: Freshfields Bruckhaus Deringer (‘Freshfields’) is advising UBS Group as global transaction counsel. UBS counsel also include Bär & Karrer and Davis Polk. For Credit
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
CODE41, a community-centric Swiss watchmaking company, has increased its share capital by issuing participation certificates in the form of ledger-based securities, thanks to the tokenisation technology of Taurus and the opensource smart contract published by
